vs

Side-by-side financial comparison of AIR LEASE CORP (AL) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

AIR LEASE CORP is the larger business by last-quarter revenue ($140.8M vs $77.6M, roughly 1.8× Bioceres Crop Solutions Corp.). AIR LEASE CORP runs the higher net margin — 128.5% vs -9.6%, a 138.1% gap on every dollar of revenue. On growth, AIR LEASE CORP posted the faster year-over-year revenue change (90.4% vs -16.8%). Over the past eight quarters, AIR LEASE CORP's revenue compounded faster (69.6% CAGR vs -8.4%).

Air Lease Corporation (ALC) is an American aircraft leasing company founded in 2010 and headed by Steven F. Udvar-Házy. Air Lease purchases new commercial aircraft through direct orders from Boeing, Airbus, Embraer and ATR, and leases them to its airline customers worldwide through specialized aircraft leasing and financing.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

AL vs BIOX — Head-to-Head

Bigger by revenue
AL
AL
1.8× larger
AL
$140.8M
$77.6M
BIOX
Growing faster (revenue YoY)
AL
AL
+107.3% gap
AL
90.4%
-16.8%
BIOX
Higher net margin
AL
AL
138.1% more per $
AL
128.5%
-9.6%
BIOX
Faster 2-yr revenue CAGR
AL
AL
Annualised
AL
69.6%
-8.4%
BIOX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AL
AL
BIOX
BIOX
Revenue
$140.8M
$77.6M
Net Profit
$180.9M
$-7.4M
Gross Margin
46.8%
Operating Margin
9.3%
Net Margin
128.5%
-9.6%
Revenue YoY
90.4%
-16.8%
Net Profit YoY
60.2%
-20.2%
EPS (diluted)
$1.49
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AL
AL
BIOX
BIOX
Q4 25
$140.8M
Q3 25
$44.5M
$77.6M
Q2 25
$53.0M
Q1 25
$92.9M
$60.6M
Q4 24
$74.0M
$98.8M
Q3 24
$65.0M
$93.3M
Q2 24
$57.8M
Q1 24
$49.0M
$84.0M
Net Profit
AL
AL
BIOX
BIOX
Q4 25
$180.9M
Q3 25
$146.5M
$-7.4M
Q2 25
$385.2M
Q1 25
$375.8M
$-1.6M
Q4 24
$112.9M
$605.2K
Q3 24
$104.0M
$-6.2M
Q2 24
$102.9M
Q1 24
$107.9M
$9.8M
Gross Margin
AL
AL
BIOX
BIOX
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
AL
AL
BIOX
BIOX
Q4 25
Q3 25
9.3%
Q2 25
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q2 24
Q1 24
15.7%
Net Margin
AL
AL
BIOX
BIOX
Q4 25
128.5%
Q3 25
329.2%
-9.6%
Q2 25
726.9%
Q1 25
404.5%
-2.6%
Q4 24
152.7%
0.6%
Q3 24
160.0%
-6.6%
Q2 24
178.2%
Q1 24
220.2%
11.6%
EPS (diluted)
AL
AL
BIOX
BIOX
Q4 25
$1.49
Q3 25
$1.21
$-0.12
Q2 25
$3.33
Q1 25
$3.26
$-0.02
Q4 24
$0.83
$0.00
Q3 24
$0.82
$-0.10
Q2 24
$0.81
Q1 24
$0.87
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AL
AL
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$466.4M
$15.5M
Total DebtLower is stronger
$19.7B
Stockholders' EquityBook value
$8.5B
$288.3M
Total Assets
$32.9B
$734.9M
Debt / EquityLower = less leverage
2.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AL
AL
BIOX
BIOX
Q4 25
$466.4M
Q3 25
$452.2M
$15.5M
Q2 25
$454.8M
Q1 25
$456.6M
$38.5M
Q4 24
$472.6M
$29.2M
Q3 24
$460.8M
$32.3M
Q2 24
$454.1M
Q1 24
$554.4M
$16.4M
Total Debt
AL
AL
BIOX
BIOX
Q4 25
$19.7B
Q3 25
$20.2B
Q2 25
$20.3B
Q1 25
$19.9B
Q4 24
$20.2B
Q3 24
$20.2B
Q2 24
$19.7B
Q1 24
$19.5B
Stockholders' Equity
AL
AL
BIOX
BIOX
Q4 25
$8.5B
Q3 25
$8.3B
$288.3M
Q2 25
$8.2B
Q1 25
$7.9B
$345.0M
Q4 24
$7.5B
$346.3M
Q3 24
$7.7B
$346.0M
Q2 24
$7.3B
Q1 24
$7.2B
$348.5M
Total Assets
AL
AL
BIOX
BIOX
Q4 25
$32.9B
Q3 25
$33.4B
$734.9M
Q2 25
$33.3B
Q1 25
$32.4B
$798.2M
Q4 24
$32.3B
$835.2M
Q3 24
$32.2B
$827.3M
Q2 24
$31.0B
Q1 24
$30.9B
$836.1M
Debt / Equity
AL
AL
BIOX
BIOX
Q4 25
2.33×
Q3 25
2.42×
Q2 25
2.47×
Q1 25
2.53×
Q4 24
2.68×
Q3 24
2.63×
Q2 24
2.69×
Q1 24
2.69×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AL
AL
BIOX
BIOX
Operating Cash FlowLast quarter
$414.1M
$14.4M
Free Cash FlowOCF − Capex
$342.1M
FCF MarginFCF / Revenue
242.9%
Capex IntensityCapex / Revenue
51.1%
Cash ConversionOCF / Net Profit
2.29×
TTM Free Cash FlowTrailing 4 quarters
$1.5B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AL
AL
BIOX
BIOX
Q4 25
$414.1M
Q3 25
$458.6M
$14.4M
Q2 25
$473.6M
Q1 25
$388.3M
$23.3M
Q4 24
$430.0M
$-5.4M
Q3 24
$461.9M
$5.2M
Q2 24
$413.8M
Q1 24
$371.3M
$-17.4M
Free Cash Flow
AL
AL
BIOX
BIOX
Q4 25
$342.1M
Q3 25
$412.3M
Q2 25
$427.1M
Q1 25
$315.5M
Q4 24
$326.8M
Q3 24
$369.8M
Q2 24
$346.4M
Q1 24
$246.8M
FCF Margin
AL
AL
BIOX
BIOX
Q4 25
242.9%
Q3 25
926.6%
Q2 25
806.0%
Q1 25
339.5%
Q4 24
441.8%
Q3 24
569.1%
Q2 24
599.5%
Q1 24
503.8%
Capex Intensity
AL
AL
BIOX
BIOX
Q4 25
51.1%
Q3 25
104.1%
Q2 25
87.8%
Q1 25
78.4%
Q4 24
139.6%
Q3 24
141.7%
Q2 24
116.7%
Q1 24
254.3%
Cash Conversion
AL
AL
BIOX
BIOX
Q4 25
2.29×
Q3 25
3.13×
Q2 25
1.23×
Q1 25
1.03×
Q4 24
3.81×
-8.85×
Q3 24
4.44×
Q2 24
4.02×
Q1 24
3.44×
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons